Fragment-based deconstruction of Bcl-xL inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 6, 2010, Pages 2577-2588

  Barelier, Sarah ^a   Pons, Julien ^a   Marcillat, Olivier ^b   Lancelin, Jean Marc ^a   Krimm, Isabelle ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(4 CHLOROPHENYL)THIO] 3 NITROBENZOYL]BENZOIC ACID; 3 IODO 5 CHLORO N [2 CHLORO 5 [(4 CHLOROPHENYL)SULFONYL]PHENYL] 2 HYDROXYBENZAMIDE; 4 (1,3 BENZODIOXOL 5 YL) 6 (2 HYDROXYPHENYL) 2 OXO 1,2 DIHYDROPYRIDINE 3 CARBONITRILE; 4 (3 MORPHOLIN 4 YL 1 PHENYLSULFANYLMETHYLPROPYLAMINO) N [4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYLCYCLOHEX 1 ENYLMETHYL]PIPERAZIN 1 YL]BENZOYL] 3 TRIFLUOROMETHANESULFONYLBENZENE SULFONAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; GOSSYPOL; MIPRALDEN; N [(2 TERT BUTYLBENZENESULFONYL)PHENYL] 2,3,4 TRIHYDROXY 5 (2 ISOPROPYLBENZYL)BENZAMIDE; N [4 [4 (4' CHLOROBIPHENYL 2 YLMETHYL)PIPERAZIN 1 YL]BENZOYL] 4 (3 DIMETHYLAMINO 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 NITROBENZENESULFONAMIDE; OBATOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; TW 37; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; MOLECULAR WEIGHT; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 77949837779     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100009z     Document Type: Article

References (45)

1. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discovery 2007, 6, 211-219.
2. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
3. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragmentbased lead discovery. Nat. Rev. Drug Discovery 2004, 5, 660-672.
4. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51, 3661-3680.
5. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
6. Erlanson, D. A. Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol. 2006, 17, 643-652.
7. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
8. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem. 2006, 49, 6912-6916.
9. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput.-Aided Mol. Des. 2002, 16, 741-753.
10. Chilli, A.; Williams, G.; Smith, A. G.; Blundell, T. L.; Abell, C. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J. Med. Chem. 2006, 49, 4992-5000.
11. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 2006, 2, 720-723.
12. Andersen, O. A.; Nathubhai, A.; Dixon, M. J.; Eggleston, I. M.; van Aalten, D. M. Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin. Chem. Biol. 2008, 15, 295-301.
13. Muchmore, S. W.; Sattler, M.; Liang, H.; Meadows, R. P.; Harlan, J. E.; Yoon, H. S.; Nettesheim, D.; Chang, B. S.; Thompson, C. B.; Wong, S. L.; Ng, S. L.; Fesik, S. W. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996, 381, 335-341.
14. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26, 1324-1337.
15. Yin, X. M.; Oltvai, Z. N.; Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369, 321-323.
16. Oltvai, Z. N.; Korsmeyer, S. J. Checkpoints of dueling dimers foil death wishes. Cell 1994, 79, 189-192.
17. Kang, M. H.; Reynolds, C. P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15, 1126-1132.
18. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275, 983-986.
19. Lugovskoy, A. A.; Degterev, A. I.; Fahmy, A. F.; Zhou, P.; Gross, J. D.; Yuan, J.; Wagner, G. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of smallmolecule Bcl-2 inhibitors. J. Am. Chem. Soc. 2002, 124, 1234-1240.
20. Mohammad, R. M.; Goustin, A. S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin. Cancer Res. 2007, 13, 2226-2235.
21. Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy Madiraju, S. R.; Goulet, D.; Viallet, J.; Belec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R. W.; Beauparlant, P.; Shore, G. C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19512-19517.
22. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A.M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
23. Prakesch, M.; Denisov, A. Y.; Naim, M.; Gehring, K.; Arya, P. The discovery of small molecule chemical probes of Bcl-X(L) and Mcl-1. Bioorg. Med. Chem. 2008, 16, 7443-7449.
24. Qiu, J.; Levin, L. R.; Buck, J.; Reidenberg, M. M. Different pathways of cell killing by gossypol enantiomers. Exp. Biol. Med. (Maywood, NJ, U S.) 2002, 227, 398-401.
25. Rega, M. F.; Leone, M.; Jung, D.; Cotton, N. J.; Stebbins, J. L.; Pellecchia, M. Structure-based discovery of a new class of Bcl-xL antagonists. Bioorg. Chem. 2007, 35, 344-353.
26. Schwartz, P. S.; Manion, M. K.; Emerson, C. B.; Fry, J. S.; Schulz, C. M.; Sweet, I. R.; Hockenbery, D. M. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition. Mol. Cancer Ther. 2007, 5, 2073-2080.
27. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: apotentand orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68, 3421-3428.
28. Wang, J. L.; Liu, D.; Zhang, Z. J.; Shan, S.; Han, X.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7124-7129.
29. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J. C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003, 63, 8118-8121.
30. Dalvit, C.; Fogliatto, G.; Stewart, A.; Veronesi, M.; Stockman, B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 2001, 21, 349-359.
31. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 2000, 18, 65-68.
32. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem., Int. Ed. 1999, 38, 1784-1788.
33. Meinecke, R.; Meyer, B. Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaIIbbeta3. J. Med. Chem. 2001, 44, 3059-3065.
34. Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem. 2006, 49, 656-662.
35. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "rule of three" for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877.
36. Lee, E. F.; Czabotar, P. E.; Smith, B. J.; Deshayes, K.; Zobel, K.; Colman, P. M.; Fairlie, W. D. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 2007, 14, 1711-1713.
37. Becattini, B.; Kitada, S.; Leone, M.; Monosov, E.; Chandler, S.; Zhai, D.; Kipps, T. J.; Reed, J. C.; Pellecchia, M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem. Biol. 2004, 11, 389-395.
38. Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J. C.; Pellecchia, M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 2003, 46, 4259-4264.
39. Wang, G.; Nikolovska-Coleska, Z.; Yang, C. Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; Meagher, J.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P. P.; Abaan, H. O.; Tomita, Y.; Wang, S. Structure-based design of potent smallmolecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem. 2006, 49, 6139-6142.
40. Verdonk, M. L.; Rees, D. C. Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem 2008, 5, 1179-1180.
41. Stout, T. J.; Sage, C. R.; Stroud, R. M. The additivity of substrate fragments in enzyme-ligand binding. Structure 1998, 5, 839-848.
42. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 5, 277-293.
43. Johnson, B. A.; Blevins, R. A. NMR View, a computer-program for the visualization and analysis of NMR data. J. Biomol. NMR 1994, 4, 602-614.
44. Bretonnet, A. S.; Jochum, A.; Walker, O.; Krimm, I.; Goekjian, P.; Marcillat, O.; Lancelin, J. M. NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site. J. Med. Chem. 2007, 50, 1865-1875.
45. Morris, G. M.; Huey, R.; Olson, A. J. Using AutoDock for Ligand-Receptor Docking. In Current Protocols in Bioinformatics; Wiley: Somerset, NJ, 2008; Chapter 8, Unit 8, p 14.